Analyses of patients who self-administered diazepam nasal spray for acute treatment of seizure clusters.

Publication/Presentation Date

1-1-2024

Abstract

For acute treatment of seizure clusters in patients with epilepsy, intranasal administration of acute seizure therapies has been shown to provide accessibility and ease of use to care partners as well as the potential for self-administration by patients. Diazepam nasal spray (Valtoco®) was approved by the US Food and Drug Administration for acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) in patients with epilepsy aged ≥6 years. Self-administration consistent with the prescribing information is feasible and was reported by a subgroup of patients (n = 27 of 163) in a long-term phase 3 safety study. Data regarding self-administration among these patients with seizure clusters are examined here to explore the safety profiles and measures of effectiveness, as well as the quality of life of those who self-treated. In addition, this focused look at patients who self-administered diazepam nasal spray may offer some insights into the characteristics of patients who may be appropriate for self-administration.

Volume

25

First Page

100644

Last Page

100644

ISSN

2589-9864

Disciplines

Medicine and Health Sciences

PubMedID

38274142

Department(s)

Department of Medicine

Document Type

Article

Link to Full Text

Share

COinS